Precigen Q1: PAPZIMEOS nets $21.6M revenue; loss narrows to $7.9M

PRECIGEN, INC.

2026-Q1 EPS reported -$0.02 vs consensus -$0.03 ▲ beat (+38.7%)

Net product revenue from PAPZIMEOS was $21.6M in Q1 2026, first full quarter post-FDA approval.
Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025.
Patient hub enrollment reached ~400 patients; 25% from community settings.
Cash, equivalents, and investments totaled $56.7M as of March 31, 2026.
Permanent J-code (J3404) assigned effective April 1, 2026, expected to streamline access.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECIGEN, INC. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 13, 2026, reporting its financial results for the quarter ended March 31, 2026.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

PRECIGEN, INC. filing history →

Source: SEC EDGAR

accession 0000950103-26-007158

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.